Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
Cell Metabolism · 2024-10 · 36 (10) · 2190-2206.e5
DOI: 10.1016/j.cmet.2024.07.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Metabolism, 2024-10. Verfasst von Liang Tao und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, …. Hauptthemen laut MEDLINE: Fatty Liver, Iron. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China; The Second Affiliat…
- The Second Affiliated Hospital, The First Affiliated Hospital, Institute of Translational Medicine, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangz…
- School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China.
- Department of Biostatistics and Medical Record, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medi…
- Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Förderung
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
Zitieren
APA
Tao, L., Yang, X., Ge, C., Zhang, P., He, W., Xu, X., Li, X., Chen, W., Yu, Y., Zhang, H., Chen, S. D., Pan, X. Y., Su, Y., Xu, C., Yu, Y., Zheng, M. H., Min, J., & Wang, F. (2024). Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metabolism, 36(10), 2190-2206.e5. https://doi.org/10.1016/j.cmet.2024.07.013
Vancouver
Tao L, Yang X, Ge C, Zhang P, He W, Xu X, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metabolism. 2024;36(10):2190-2206.e5. doi:10.1016/j.cmet.2024.07.013
BibTeX
@article{Tao2024,
author = {Tao, Liang and Yang, Xinquan and Ge, Chaodong and Zhang, Peng and He, Wenjian and Xu, Xingbo and Li, Xin and Chen, Wenteng and Yu, Yingying and Zhang, Huai and Chen, Sui-Dan and Pan, Xiao-Yan and Su, Yunxing and Xu, Chengfu and Yu, Yongping and Zheng, Ming-Hua and Min, Junxia and Wang, Fudi},
title = {Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH},
journal = {Cell Metabolism},
year = {2024},
volume = {36},
number = {10},
pages = {2190--2206.e5},
doi = {10.1016/j.cmet.2024.07.013}
}
EUVIMED